Revance Therapeutics Statistics
Total Valuation
EPA:MLPRI has a market cap or net worth of EUR 18.15 million. The enterprise value is 22.87 million.
Market Cap | 18.15M |
Enterprise Value | 22.87M |
Important Dates
The last earnings date was Friday, June 20, 2025.
Earnings Date | Jun 20, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
EPA:MLPRI has 889,765 shares outstanding. The number of shares has decreased by -11.02% in one year.
Current Share Class | 889,765 |
Shares Outstanding | 889,765 |
Shares Change (YoY) | -11.02% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | n/a |
Valuation Ratios
The trailing PE ratio is 45.17.
Price/FFO Ratio | n/a |
Price/AFFO Ratio | n/a |
PE Ratio | 45.17 |
Forward PE | n/a |
PS Ratio | 21.56 |
PB Ratio | 1.08 |
P/TBV Ratio | 1.08 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | 56.91 |
EV / Sales | 27.15 |
EV / EBITDA | 50.31 |
EV / EBIT | 53.70 |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.79, with a Debt / Equity ratio of 0.31.
Current Ratio | 3.79 |
Quick Ratio | 2.56 |
Debt / Equity | 0.31 |
Debt / EBITDA | 11.40 |
Debt / FCF | n/a |
Interest Coverage | 2.69 |
Financial Efficiency
Return on equity (ROE) is 2.43% and return on invested capital (ROIC) is 1.23%.
Return on Equity (ROE) | 2.43% |
Return on Assets (ROA) | 1.21% |
Return on Invested Capital (ROIC) | 1.23% |
Return on Capital Employed (ROCE) | 2.34% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.04 |
Inventory Turnover | 0.06 |
Taxes
In the past 12 months, EPA:MLPRI has paid 388,249 in taxes.
Income Tax | 388,249 |
Effective Tax Rate | 49.14% |
Stock Price Statistics
The stock price has decreased by -18.40% in the last 52 weeks. The beta is 0.21, so EPA:MLPRI's price volatility has been lower than the market average.
Beta (5Y) | 0.21 |
52-Week Price Change | -18.40% |
50-Day Moving Average | 20.40 |
200-Day Moving Average | 21.38 |
Relative Strength Index (RSI) | 0.00 |
Average Volume (20 Days) | n/a |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, EPA:MLPRI had revenue of EUR 842,067 and earned 401,811 in profits. Earnings per share was 0.45.
Revenue | 842,067 |
Gross Profit | 555,313 |
Operating Income | 425,825 |
Pretax Income | 790,060 |
Net Income | 401,811 |
EBITDA | 454,523 |
EBIT | 425,825 |
Earnings Per Share (EPS) | 0.45 |
Balance Sheet
The company has 467,699 in cash and 5.18 million in debt, giving a net cash position of -4.71 million or -5.30 per share.
Cash & Cash Equivalents | 467,699 |
Total Debt | 5.18M |
Net Cash | -4.71M |
Net Cash Per Share | -5.30 |
Equity (Book Value) | 16.75M |
Book Value Per Share | 18.82 |
Working Capital | 11.55M |
Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross margin is 65.95%, with operating and profit margins of 50.57% and 47.72%.
Gross Margin | 65.95% |
Operating Margin | 50.57% |
Pretax Margin | 93.82% |
Profit Margin | 47.72% |
EBITDA Margin | 53.98% |
EBIT Margin | 50.57% |
FCF Margin | n/a |
Dividends & Yields
EPA:MLPRI does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 11.02% |
Shareholder Yield | n/a |
Earnings Yield | 2.21% |
FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | |
Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 3 |